Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-25-000063
Filing Date
2025-01-22
Accepted
2025-01-22 16:17:28
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 16044
2 JOINT FILING AGREEMENT ss4352919_ex9901.htm EX-99.1 5684
  Complete submission text file 0000947871-25-000063.txt   23578
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Subject) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-89495 | Film No.: 25546178
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD. 190 ELGIN AVENUE GEORGE TOWN E9 KYI-9007
Business Address C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD. 190 ELGIN AVENUE GEORGE TOWN E9 KYI-9007 962 6 582 7999
GMS Ventures & Investments (Filed by) CIK: 0001804598 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13D/A